A process for the preparation of sitagliptin of the formula II or a pharmaceutically acceptable salt thereof.

Provided are crystalline and amorphous vilazodone hydrochloride. Further provided are amorphous solid dispersions of vilazodone hydrochloride with pharmaceutically acceptable carries. Also provided is a process for the preparation of form I of vilazodone free base.

Aspects of the present invention relate to rasagiline, proceeses for the preparation of rasagiline, and pharmaceutically acceptable salts thereof.

The present application relate to amorphous form of Apixaban useful in making pharmaceutically acceptable dosage forms, and to processes for their preparation.

The present application relates to amine salts of prostaglandin analogs and their uses for the preparation of substantially pure prostaglandin analogs. Specific embodiments relate to amine salts of tafluprost and their uses for the preparation of substantially pure tafluprost.

Disclosed are crystalline forms of pitavastatin calcium and processes for their preparation and isolation. Pharmaceutical compositions comprising said crystalline forms are provided also.

The present application provides improved processes for crystallization of Rasagiline hemitartrate having improved filterability.

The present disclosure provides pharmaceutical compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the compositions devoid of buffer and in the presence of alkaline oxides capable of raising the pH of saliva to a pH greater than about 7.0 thereby facilitate the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surp...